HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Ondansetron (Zofran)

Subscribe to New Research on Ondansetron

A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.

Also Known As:

Zofran; SN 307; GR-38032F; GR38032F; Ondansetron Hydrochloride; Ondansetron Monohydrochloride; Ondansetron Monohydrochloride Dihydrate; Ondansetron, (+,-)-Isomer; Ondansetron, (R)-Isomer; Ondansetron, (S)-Isomer; SN-307; Dihydrate, Ondansetron Monohydrochloride; GR 38032F; Hydrochloride, Ondansetron; Monohydrochloride Dihydrate, Ondansetron; Monohydrochloride, Ondansetron; SN307; 4H-Carbazol-4-one, 1,2,3,9-tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-

Networked: 1871 relevant articles (552 outcomes, 615 trials/studies)

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 60

Experts

1.	Gan, Tong J: 17 articles (01/2014 - 04/2002)
2.	Freedman, Stephen B: 11 articles (02/2015 - 04/2006)
3.	Rudd, John A: 11 articles (08/2014 - 11/2002)
4.	Habib, Ashraf S: 8 articles (06/2013 - 07/2004)
5.	Apfel, Christian C: 7 articles (11/2013 - 01/2004)
6.	Johnson, Bankole A: 7 articles (09/2013 - 09/2003)
7.	Fujii, Yoshitaka: 7 articles (12/2011 - 01/2005)
8.	Parker, Linda A: 6 articles (08/2014 - 07/2004)
9.	Porreca, Frank: 6 articles (08/2013 - 05/2007)
10.	Carides, Alexandra D: 6 articles (06/2011 - 06/2002)

Related Diseases

1.	Vomiting 01/01/1999 - "However, there was a significant reduction in emesis management costs for patients treated after versus before the availability of ondansetron: for patients treated in the last third versus first third of the study period, there was a decrease in cost per patient per month of treatment of $374 (95% confidence interval, $243 to $505). " 03/01/1996 - "The need for antiemetic rescue therapy (ondansetron 0.15 mg/kg intravenously after three episodes of emesis prior to discharge) was significantly greater in children who received placebo compared with the ondansetron 0.15 mg/kg study group (13% vs 0%, P < 0.05). " 11/01/2012 - "In conclusion, the administration of oral ondansetron to children with vomiting in the emergency department is clinically effective and results in significant economic savings." 12/01/2001 - "The incidence of vomiting was significantly greater after infusion of placebo than after either low-dose or high-dose ondansetron. " 12/01/1997 - "All doses of ondansetron 0.05 mg/kg, 0.1 mg/kg, and 0.15 mg/kg were significantly more effective than placebo in reducing the incidence of emesis prior to, following discharge, and during the first 24 postoperative hours (p < 0.001). "
2.	Postoperative Nausea and Vomiting (PONV) 01/01/1994 - "In conclusion ondansetron given preoperatively had proven to be an effective treatment for PONV after epidural block for lower abdominal surgery." 02/01/1994 - "Clearance has been received from the Food and Drug Administration for marketing of Zofran injection for the prevention of postoperative nausea and vomiting, at a dose of 4 mg IV over 2 to 5 min. Zofran has been evaluated in clinical studies with good results in the reduction or prevention of postoperative nausea and vomiting with minimal adverse reactions." 12/01/1999 - "We evaluated the antiemetic efficacy, safety, and routine use of prophylactic ondansetron, a "gold standard" antiemetic, in women undergoing radical breast surgery who were at a high risk of postoperative vomiting. " 01/01/1999 - "Ondansetron, a selective serotonergic antagonist, is effective in reducing postoperative nausea and vomiting in several high-risk populations. " 08/01/1996 - "Ondansetron, a selective serotonergic (5-HT3) antagonist, is effective in reducing postoperative vomiting in several high-risk populations. "
3.	Nausea 03/01/2008 - "However, the latter improved nausea on day 2. A single 8 mg dose of ondansetron can maintain antiemetic efficacy in the majority of complete responders in arm A and arm B." 05/01/1994 - "The two schedules of ondansetron used in the first 24 hours were no different in their antiemetic efficacy, with similar rates for complete responses (76.7% v 72.0%, P = .472), complete plus major responses (90.2% v 82.0%, P = .135), and severity of nausea (P = .348). " 10/01/2012 - "The addition of ondansetron ODT resulted in a significant improvement in degree of nausea." 10/01/2012 - "Conversely, during phase 2, patients receiving ondansetron ODT showed significant improvement in both measures of nausea. " 07/01/2001 - "There was a significant reduction in the frequency of emetic episodes and rescue antiemetic requirement in patients treated with ondansetron; however, ondansetron did not significantly reduce the incidence of nausea alone (14% in Group 2 vs 5% in Group 1, P = .065). "
4.	Neoplasms (Cancer) 01/30/2006 - "Furthermore, the effects of ondansetron were significantly greater in cancer animals compared to shams. " 03/01/2005 - "A prospective randomized trial of the antiemetic efficacy and cost-effectiveness of intravenous and orally disintegrating tablet of ondansetron in children with cancer." 12/01/1992 - "Priestman (Eur J Cancer Clin Oncol 25:529-533, 1989 [Suppl]) reported on a pilot and randomized study with ondansetron after single doses of 8 to 10 Gy to the upper abdomen. " 12/01/1992 - "The safety of intravenous (IV) and oral ondansetron has been evaluated in over 7,000 cancer patients in world-wide clinical trials. " 01/01/1992 - "Ondansetron was given as anti-emetic prophylaxis to 429 children receiving a variety of emetogenic cancer treatments for up to 8 days, in three, open, multicentre, European studies. "
5.	Pruritus (Itching) 10/01/1998 - "Although under treatment with ondansetron a significant improvement of itching as assessed by the VAS score was demonstrated, this treatment was not preferred over placebo by the patients. " 03/01/1999 - "We have evaluated the efficacy of ondansetron in the prevention of opioid-induced pruritus in a prospective, randomized, double-blind, placebo-controlled study. " 11/01/2012 - "Ondansetron was demonstrated to have negligible effect on cholestatic or uremic pruritus on the basis of a limited number of studies." 11/01/2012 - "Overall, three studies showed no benefit to ondansetron over placebo; however, two studies in cholestatic pruritus showed small reductions in pruritus with questionable clinical significance. " 11/01/2012 - "Electronic databases were systematically searched for randomized controlled trials examining the role of ondansetron in cholestatic or uremic pruritus between 1966 and 2008. "

Related Drugs and Biologics

1.	Dexamethasone (Maxidex)
2.	Metoclopramide (Reglan)
3.	Cisplatin (Platino)
4.	Droperidol
5.	Granisetron (Kytril)
6.	Serotonin (5 Hydroxytryptamine)
7.	Cyclophosphamide (Cytoxan)
8.	ramosetron (Nasea)
9.	Antiemetics
10.	Ondansetron (Zofran)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Laparoscopic Cholecystectomy
3.	General Anesthesia
4.	Tonsillectomy
5.	Patient-Controlled Analgesia (Analgesia, Patient Controlled)